These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6750029)

  • 41. Passive inhalation of marihuana smoke and urinary excretion of cannabinoids.
    Perez-Reyes M; Di Guiseppi S; Mason AP; Davis KH
    Clin Pharmacol Ther; 1983 Jul; 34(1):36-41. PubMed ID: 6305545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interference of common household chemicals in immunoassay methods for drugs of abuse.
    Warner A
    Clin Chem; 1989 Apr; 35(4):648-51. PubMed ID: 2539273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of the MTP immunoassay with EMIT in blood screening for drugs].
    Käferstein H; Sticht G
    Arch Kriminol; 1998; 202(5-6):165-72. PubMed ID: 10023491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laboratory evaluation of immunoassay kits for the detection of cannabinoids in biological fluids.
    Peat MA; Finkle BS; Deyman ME
    NIDA Res Monogr; 1982; 42():85-98. PubMed ID: 6817140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and evaluation of immunochromatographic rapid tests for screening of cannabinoids, cocaine, and opiates in urine.
    Wennig R; Moeller MR; Haguenoer JM; Marocchi A; Zoppi F; Smith BL; de la Torre R; Carstensen CA; Goerlach-Graw A; Schaeffler J; Leinberger R
    J Anal Toxicol; 1998; 22(2):148-55. PubMed ID: 9547412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The determination of drugs of abuse in whole blood by means of FPIA and EMIT-dau immunoassays--a comparative study.
    Bogusz M; Aderjan R; Schmitt G; Nadler E; Neureither B
    Forensic Sci Int; 1990 Nov; 48(1):27-37. PubMed ID: 2279719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users.
    Ellis GM; Mann MA; Judson BA; Schramm NT; Tashchian A
    Clin Pharmacol Ther; 1985 Nov; 38(5):572-8. PubMed ID: 3902318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke.
    Cone EJ; Johnson RE
    Clin Pharmacol Ther; 1986 Sep; 40(3):247-56. PubMed ID: 3017628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects.
    McBurney LJ; Bobbie BA; Sepp LA
    J Anal Toxicol; 1986; 10(2):56-64. PubMed ID: 3009969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens.
    Arntson A; Ofsa B; Lancaster D; Simon JR; McMullin M; Logan B
    J Anal Toxicol; 2013 Jun; 37(5):284-90. PubMed ID: 23625703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme multiplied immunoassay technique: a review.
    Curtis EG; Patel JA
    CRC Crit Rev Clin Lab Sci; 1978; 9(4):303-20. PubMed ID: 401373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification and evaluation of Abuscreen OnLine assays for drug metabolites in urine performed on a COBAS FARA II in comparison with EMIT d.a.u. Cannabinoid 20.
    Hailer M; Glienke Y; Schwab IM; von Meyer L
    J Anal Toxicol; 1995; 19(2):99-103. PubMed ID: 7769796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct and indirect homogeneous enzyme immunoassay of benzodiazepines in biological fluids and tissues.
    Slightom EL; Cagle JC; McCurdy HH; Castagna F
    J Anal Toxicol; 1982; 6(1):22-5. PubMed ID: 7043088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for drugs in forensic blood samples using EMIT urine assays.
    Gjerde H; Christophersen AS; Skuterud B; Klemetsen K; Mørland J
    Forensic Sci Int; 1990 Feb; 44(2-3):179-85. PubMed ID: 2180797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a radioimmunoassay (125I) kit for cannabinoid metabolites in urine and whole blood.
    Childs PS; McCurdy HH
    J Anal Toxicol; 1984; 8(5):220-3. PubMed ID: 6503225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunospecificity differences between Roche fluorescence polarization immunoassay and Syva EMIT assay of quinidine.
    Malikin G; Lam S
    Clin Chem; 1992 Apr; 38(4):603-5. PubMed ID: 1568340
    [No Abstract]   [Full Text] [Related]  

  • 57. Human cannabinoid pharmacokinetics.
    Huestis MA
    Chem Biodivers; 2007 Aug; 4(8):1770-804. PubMed ID: 17712819
    [No Abstract]   [Full Text] [Related]  

  • 58. Valproic acid estimation by enzyme immunoassay.
    Elyas AA; Goldberg VD; Ratnaraj N; Lascelles PT
    Ann Clin Biochem; 1980 Nov; 17(6):307-10. PubMed ID: 6782934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of interference by nabilone in the EMIT d.a.u. cannabinoid assay, Abbott TDx cannabinoid assay, and a sensitive TLC assay for delta 9-THC-carboxylic acid.
    Fraser AD; Meatherall R
    J Anal Toxicol; 1989; 13(4):240. PubMed ID: 2550703
    [No Abstract]   [Full Text] [Related]  

  • 60. Cannabinoids in blood and urine after passive inhalation of Cannabis smoke.
    Mørland J; Bugge A; Skuterud B; Steen A; Wethe GH; Kjeldsen T
    J Forensic Sci; 1985 Oct; 30(4):997-1002. PubMed ID: 2999292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.